Alkermes To Put Its Long-Acting Stamp On Trusted Blockbusters, Starting With Abilify
This article was originally published in The Pink Sheet Daily
Executive Summary
Alkermes unveils patented, monthly injectable form of aripiprazole, developed without Bristol/Otsuka. Up next: Pfizer/Amgen's Enbrel.
You may also be interested in...
Alkermes Unveils Bydureon Royalties And Its Own Long-acting Form Of Lilly's Zyprexa
Risperdal Consta will be cash cow for years to come, but other drugs in pipeline will fill out revenue stream.
Alkermes Unveils Bydureon Royalties And Its Own Long-acting Form Of Lilly's Zyprexa
Risperdal Consta will be cash cow for years to come, but other drugs in pipeline will fill out revenue stream.
Apotex Manufacturing Violations Could Delay Launch Of Taxotere Generic
FDA's warning letter to Apotex for continued manufacturing violations could delay the launch of the company's generic version of the cancer drug Taxotere (docetaxel)